Preimplantation Genetic Testing Market to Reach USD 465.1 Million by 2026 at a CAGR of 8.7%

Increasing awareness about pregnancy & childbirth, aging & menopause, fertility management, and sexual health worldwide are primary factors driving the demand for PGT. Moreover, an increase in the adoption of IVF procedures can be seen as a result of late marriages, infertility, and growing ambitious population in the developing regions. One in each four couples in the developing countries is affected by infertility. Moreover, PGD benefits the couples suffering from hereditary disorders, which, in turn, is driving demand for preimplantation genetic testing. With increasing infertility in men, some of the start-ups are helping males in solving their erectile-dysfunction predicament by providing appropriate drugs online. Increasing Initiatives to Promote Healthy Pregnancies Preimplantation genetic testing, by type, is segmented into the preimplantation genetic screening, preimplantation genetic diagnosis. PGD segment is accounting for the largest market share during the forecast period. Moreover, increasing government efforts to support healthy pregnancies are progressing the market. For instance, in 2017, the Switzerland government passed a medial law to allow pre-implantation genetic diagnosis. As per Switzerland government, around 500–1,000 couples every year undergo IVF treatment. Moreover, to lessen the burden on families and to promote IVF in developing countries, many banks provide EMI’s for treatment. For instance, in india, Bajaj Finance offer lifecare  maternity care and IVF treatment. It is available in 400 cities and in partnership with over 2700 hospitals to cover a wide population. Product & service segment is divided into reagents & consumables, instruments, and software & services. The reagents & consumables segment is generating the highest revenue following increasing applications of diagnostic technologies. Asia Pacific to Witness Growth in the Demand for Preimplantation Genetic Testing Got questions about your regional growth of Preimplantation Genetic Testing Market ? Just drop us a line or call on +1 646 480 7505 Currently, Asia Pacific is witnessing significant growth in infertility rate. Late marriages, rising number of singles, preference for no children, and higher divorce rates are major factors affecting the fertility. According to the Indian Society of Assisted Reproduction, infertility affects about 10%-14% of the Indian population. Moreover, in Australia and New Zealand, 1 in 6 couples suffers from infertility, Fertility Society of Australia. Apart from this, the Australian government is providing infertile couples with insurance coverage to promote the benefits of IVFin the region. Japan, Singapore, and South Korea’s total fertility rate have been plummeted to 1.44, 1.20, and 1.17, respectively, the World Bank. Hong Kong has one of the lowest fertility rates in the world, which is adding fuel to the demand for PGT and IVF in this region. In India, data-driven fertility program Elawoman has raised USD 3 million in funding by Chiratae Ventures. The Middle East and Africa are offering significant growth opportunities in the global preimplantation genetic testing market. Moreover, the outbreak of zika virus in Africa has increased the cases of preterm birth, miscarriages, and microcephaly. In the Middle East, congenital malformations are one of the leading causes of infant mortality, WHO. Competitive Landscape Several key players are taking continuous efforts for developing  innovative products and expanding market presence. In 2018, Natera, a prominent leader in non-invasive genetic testing, shared a study on spectrum preimplantation genetic screening, innovative technology to improve IVF outcomes. Spectrum PGT-A is found to reduce the negative risks for IVF by allowing only suitable embryos. In 2018, Illumina Inc. entered into an agreement with Vitrolife AB. In this, Vitrolife will distribute Illumina’s PGT products in America and EMEA. Some of the other players active in the market are Illumina, Inc, SciGene Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Yikon Genomics. Preimplantation Genetic Testing Market Segmentation  By Procedure Type Preimplantation Genetic Screening Preimplantation Genetic Diagnosis By Technology Next-Generation Sequencing Polymerase Chain Reaction Fluorescence in Situ Hybridization Comparative Genomic Hybridization Single-Nucleotide Polymorphism By Product and Service Reagents and Consumables Instruments Software and Services By Application Aneuploidy Screening Structural Chromosomal Abnormalities Translocations Deletions Duplications Inversions X-Linked Disorders HLA Typing Single Gene Disorder Screening Gender Identification By End User Hospitals Diagnostic Laboratories Research & Academic Centers Fertility Clinics & Maternity Centers Regions Covered America North America U.S. Canada Mexico South America Europe Western Europe UK Germany France Italy Spain Rest of Europe Eastern Europe Asia-Pacific China India Japan South Korea Australia Rest of Asia-Pacific MEA The Middle East Saudi Arabia UAE Qatar Rest of The Middle East Africa Key Players Illumina, Inc. SciGene Corporation Thermo Fisher Scientific Inc. Agilent Technologies, Inc. Yikon Genomics Oxford Gene Technology Rubicon Genomics, Inc. Natera, Inc. Abbott CooperSurgical, Inc PerkinElmer Inc " Crucial Insights The Report Provides:" * Known and Unknown Adjacencies Influencing the Growth of Market * Explorable Revenue Sources * Customer Behaviour Analysis * Target Partners * Customized Geographical Data Based on Customers as well as Competitors * Analysis of Market Size and CAGR between the Forecast Periods View Full Report Buy This Report Now